Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma.
A novel prodrug rationally designed to function as a tyrosinase substrate has been synthesised to allow targeted treatment of malignant melanoma. This agent has been evaluated for tyrosinase-mediated drug release, and has been shown to act in the desired manner. Furthermore, differential cytotoxicity has been demonstrated in cell lines which express tyrosinase and those which do not.
Jordan
A M
AM
Department of Chemistry, University of Reading, Whiteknights, UK.
Khan
T H
TH
Osborn
H M
HM
Photiou
A
A
Riley
P A
PA
D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D009682:Magnetic Resonance Spectroscopy; D008544:Melanocytes / Q000187:drug effects*; D008545:Melanoma / Q000188:drug therapy* / Q000201:enzymology; D014442:Monophenol Monooxygenase / Q000378:metabolism; D011355:Prodrugs / Q000494:pharmacology / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D011355:Prodrugs; D014442:Monophenol Monooxygenase